PHARMAC is seeking feedback on a proposal to fund preservative free prednisolone sodium phosphate 0.5% eye drops, resulting from a provisional agreement formed between Bausch & Lomb (New Zealand) Limited and PHARMAC.

In summary, this proposal would result in Listing of Minims prednisolone sodium phosphate 0.5% eye drops in Section B and pricing being added to the existing listing in Part II of Section H of the Pharmaceutical Schedule from 1 October 2015. Funding would be restricted to the treatment of patients with severe eye inflammation who are allergic to the preservative used in eye drops.

For more details, go to: http://www.pharmac.health.nz/news/new-news-page-4/